Oct 13, 2026 08:31AM
Oct 12, 2026 04:37PM
Oct 2, 2026 04:20PM
Sep 25, 2026 04:30PM
Sep 3, 2026 06:03AM
Aug 6, 2026 11:34AM
Jun 11, 2026 09:02AM NeuroSense receives South Korean patent for ALS drug PrimeC
Jun 9, 2026 09:01AM
Apr 28, 2026 02:42PM
Apr 6, 2026 09:20AM
Mar 24, 2026 09:03AM
Mar 10, 2026 02:59AM
Feb 18, 2026 09:05AM
Feb 9, 2026 09:20AM NeuroSense receives Australian patent for PrimeC drug composition
Oct 14, 2025 09:46AM
May 12, 2025 07:08AM
Apr 24, 2025 09:09AM
Apr 9, 2025 08:30AM
Apr 8, 2025 11:21AM
Jan 6, 2025 09:02AM
Dec 16, 2024 08:13AM Maxim Group Downgrades NeuroSense Therapeutics Ltd. (NRSN) to Hold
Dec 11, 2024 09:25AM
Dec 2, 2024 08:32AM
Nov 19, 2024 04:18PM
Oct 28, 2024 08:30AM
Oct 15, 2024 09:16AM
Oct 9, 2024 09:02AM
Sep 24, 2024 09:05AM Neurosense Therapeutics (NRSN) Granted Key U.S. Patent for Novel PrimeC Formulation, its Lead Asset for ALS and Alzheimer's
Sep 24, 2024 09:00AM
Aug 30, 2024 04:30PM
Aug 7, 2024 02:00PM
Aug 1, 2024 09:15AM
Jul 9, 2024 09:27AM
Jul 1, 2024 08:07AM
Jun 21, 2024 04:30PM Neurosense Therapeutics (NRSN) Receives Delisting Notice from Nasdaq, Intends to Appeal
Nov 28, 2022 11:26AM

479,039 total articles have been posted to this entity.

Click Here to Sign-Up for StreetInsider.com Premium to View All